Determinants of long-term SARS-CoV-2 immune responses in asymptomatic-to-moderate COVID-19 patients in sub-Saharan Africa
Authors:
Open Access
- 14 January 2026
- journal article
- research article
- Published by Springer Nature in BMC Medicine
- Vol. 24
Abstract
Immune responses after SARS-CoV-2 infection remain poorly characterized in African populations, despite widespread viral transmission and proportionally loKeywords
All Related Versions
Funding Information
- German Federal Ministry of Education and Research
- European & Developing Countries Clinical Trials Partnership
- Fundació Privada Daniel Bravo Andreu
- Agencia Estatal de Investigación (CEX2023-0001290-S)
- Agencia Estatal de Investigación (RYC 2020-029886-I/AEI/10.13039/501100011033)
- Centres de Recerca de Catalunya
This publication has 70 references indexed in Scilit:
- Long-lasting antibody B-cell responses to SARS-CoV-2 three years after the onset of the pandemicCell Reports, 2025
- Malaria and other infections induce polyreactive antibodies that impact SARS‐CoV‐2 seropositivity estimations in endemic settingsJournal of Medical Virology, 2024
- Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022JAMA Network Open, 2023
- Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccinationCell, 2022
- Potency of BNT162b2 and mRNA‐1273 vaccine‐induced neutralizing antibodies against severe acute respiratory syndrome‐CoV‐2 variants of concern: A systematic review of in vitro studiesReviews in Medical Virology, 2021
- Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humansCell Host & Microbe, 2021
- Association of Age With SARS-CoV-2 Antibody ResponseJAMA Network Open, 2021
- Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donorsClinical & Translational Immunology, 2021
- Comprehensive analysis of SARS‐CoV‐2 antibody dynamics in New ZealandClinical & Translational Immunology, 2021
- Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19Cell, 2020